Research programme: anti-TNF compounds - Ception Therapeutics
Latest Information Update: 27 May 2010
At a glance
- Originator Ception Therapeutics
- Class Small molecules
- Mechanism of Action Tumour necrosis factor inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Inflammation
Most Recent Events
- 31 Jan 2007 Preclinical trials in Inflammation in USA (PO)